Relationship between sputum inflammatory markers, lung function, and lung pathology on high-resolution computed tomography in children with cystic fibrosis
- 3 May 2002
- journal article
- research article
- Published by Wiley in Pediatric Pulmonology
- Vol. 33 (6) , 475-482
- https://doi.org/10.1002/ppul.10109
Abstract
High-resolution computed tomography (HRCT) is a sensitive technique for early visualisation and location of cystic fibrosis (CF) bronchopathology, and has been shown to detect acute reversible and chronic changes. It would be expected to correlate with markers of the underlying pathological processes, such as sputum cytokines and cytology, as well as with pulmonary function tests (PFTs). Our aim was to study the relationship between PFTs, sputum cytology, and sputum cytokine interleukin-8 (IL-8) and HRCT in CF patients. Prospective standardized collection of sputum samples was performed at the time of routine annual high-resolution CT scans. Forced expired volume in 1 sec (FEV1) and forced vital capacity (FVC) were recorded. Sputum processing was selective, with dispersal by the three-enzyme technique. IL-8 measurements were by kit assay. HRCT scans were scored by a pediatric radiologist, blinded to clinical condition, using a modified Bhalla score. Forty-three CT scans were performed on 34 children with CF between March 1998 and April 2000. Mean age was 12.3 years (range, 6–21 years), FEV1 (% predicted) was 67% (range, 23–120%), and mean modified Bhalla score was 11.2 (range, 0–22). Sputum IL-8 concentration (mean, 86; range, 4–150 ng/mL) and total cell count (mean, 31.9 × 106/mL; range, 21.8–42.0 × 106/mL) were high. FEV1 and FVC correlated with modified Bhalla score (r = −0.66, P < 0.0001 for both), and most individual components of the score, especially mosaic perfusion (r = −0.64, r = −0.61 respectively, P < 0.0001) and extent of bronchiectasis (r = −0.61, P < 0.0001 for both). The combination of these two predicted 58% of the variability in FEV1 on analysis of variance (P < 0.0001). Sputum total cell count correlated weakly with modified Bhalla score (r = 0.38, P < 0.05) and with FEV1 and FVC (r = −0.36, P < 0.05; and r = −0.46, P < 0.01). Differential cell counts, cell viability, and IL-8 did not correlate with modified Bhalla scores, or with reversible components such as mucus plugging, centrilobular nodules, or peribronchial thickening. In conclusion, pathological changes on HRCT correlated with lung function but not with sputum markers of inflammation. Pediatr Pulmonol. 2002; 33:475–482.Keywords
This publication has 45 references indexed in Scilit:
- Serial sputum cell counts in the management of chronic airflow limitationEuropean Respiratory Journal, 1998
- Repeatability of cellular and soluble markers of inflammation in induced sputum from patients with asthmaEuropean Respiratory Journal, 1996
- Assessment of airway inflammation in children with acute asthma using induced sputumEuropean Respiratory Journal, 1996
- A case for serial examination of sputum inflammatory cellsEuropean Respiratory Journal, 1996
- Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils.Thorax, 1996
- Analysis of induced sputum to examine the effects of prednisone on airway inflammation in asthmatic subjectsJournal of Allergy and Clinical Immunology, 1994
- Non‐invasive assessment of bronchial inflammation in asthma: no correlation between eosinophilia of induced sputum and bronchial responsiveness to inhaled hypertonic salineClinical and Experimental Allergy, 1994
- The evaluation of a cell dispersion method of sputum examinationClinical and Experimental Allergy, 1994
- Cytokines in sputum and serum from patients with cystic fibrosis and chronic pseudomonas aeruginosa infection as markers of destructive inflammation in the lungs.Pediatric Pulmonology, 1993
- Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor.Journal of Clinical Investigation, 1992